Africa HIV Drugs Market Research Report: Forecast (2024-2030)

Market Definition

HIV drugs are medications used to treat HIV infection by suppressing the replication of the virus in the body. These drugs target different stages of the HIV lifecycle, such as entry into cells, reverse transcription, integration into the host cell genome, and viral assembly and release. By inhibiting viral replication, HIV drugs help to reduce viral load, prevent the progression of HIV to AIDS, improve immune function, and prolong the lifespan of individuals living with HIV.

Market Insights & Analysis: Africa HIV Drugs Market (2024-30):

The Africa HIV Drugs Market size is estimated to grow at a CAGR of around 8.20% during the forecast period, i.e., 2024-30. The market growth has been attributed to sustainable economic growth and poverty reduction efforts that contributed to improved access to healthcare services, including HIV treatment. Africa has a large and growing population, with a high prevalence of HIV/AIDS compared to other regions. For instance,

• According to the World Health Organization (WHO), in 2022, about 25.6 million people were living with HIV in the African region, among which around 760,000 were newly infected with HIV.

Hence, this demographic factor alone has been creating a sustained demand for HIV medications across African countries during historical years. Moreover, the rising investments in healthcare facilities, clinics, and supply chains to ensure reliable access to HIV medications and services in remote and underserved areas of the region are also likely to accelerate the growth & expansion of the Africa HIV Drugs Market. Further, the collaborative efforts taken by the key companies to improve access to HIV medications in Africa are also expected to positively impact overall market growth & expansion. For instance,

• In 2023, GSK signed deals with Aurobindo Pharma, Cipla, and Viatris, allowing them to make inexpensive generic versions of its long-acting HIV preventive medicine cabotegravir for use in lower-income countries, including South Africa, where the majority of new HIV cases occur.

Hence, these efforts by the government and companies are anticipated to improve awareness regarding HIV infection among consumers. Thus, as more individuals get diagnosed with HIV, the demand for HIV treatment drugs is anticipated to increase substantially during the forecast period.

Africa HIV Drugs Market Driver:

The High Rate of HIV in African Girls & Women – The epidemiological evidence suggests that the prevalence and rates of HIV are unacceptably high among women in Africa. For instance,

• As per the Joint United Nations Programme, in 2022, adolescent girls and young women accounted for more than 77% of new infections among young people aged 15-24 years in sub-Saharan Africa.
• The UNAIDS data also highlighted that every week, 3100 adolescent girls and young women aged 15–24 years became infected with HIV in sub-Saharan Africa in 2022.

The combination of several factors, including biological, social, behavioral, cultural, economic, and structural, in sub-Saharan Africa has led to a disparate increase in HIV infection rates among women compared to their male counterparts. Thus, the rising HIV cases further necessitate that the young girls and women in the region go for proper diagnosis and treatment for HIV to avoid adverse consequences. This has been primarily because the treatment in the form of HIV drugs belonging to different classes, such as nucleoside reverse transcriptase inhibitors (NRTIs), integrase inhibitors, protease inhibitors, etc., not only allows these women with HIV to live longer, healthier lives but also reduces the risk of further HIV transmission.

Moreover, the rising awareness among African women regarding the effects of HIV drugs and their willingness to live longer and healthier lives would further augment the size & volume of the Africa HIV Drugs Market in the coming years.

Africa HIV Drugs Market Opportunity:

Expansion of Telemedicine & Mobile Health Solutions to Create New Opportunities – With the improving penetration of mobile phones and internet connectivity across Africa, specifically in countries like South Africa, Egypt, etc., there is a growing opportunity to leverage technology to improve access to HIV/AIDS care and treatment. This is primarily because access to mobile phones and the internet would allow more users to adopt telemedicine services across African countries. Telemedicine platforms would facilitate remote consultations, medication adherence monitoring, and counseling services, particularly in remote areas where access to healthcare facilities is limited. These telehealth applications would provide valuable support tools for both patients and healthcare providers, offering features such as HIV medication reminders, educational resources, and virtual support groups.

Thus, by harnessing the power of telemedicine, the African HIV Drug Industry would be able to overcome barriers related to geographical distance, transportation costs, and healthcare workforce shortages. Consequently, improving access to mobile phones and the internet, along with increasing adoption of telemedicine, would emerge as a great opportunity for enhancing the demand for HIV drugs in Africa in the coming years.

Africa HIV Drugs Market Challenge:

High Cost of HIV Drugs to Hinder Market Growth & Expansion – The high cost of HIV drugs in the African market remains a formidable challenge, impeding widespread access to life-saving medication. For instance,

In 2023, the South African Health Department mentioned that the cost of ViiV Healthcare’s HIV drug Apretude, which is between USD 28.9 to USD 30.5 after the prices had been reduced by the company, is still three times higher than its people can afford to pay.

This high cost has been attributed to the region’s limited healthcare budgets, the presence of only a few local and regional HIV drug manufacturing companies, huge dependency on imported HIV drugs that are patent protected, and dependence on donor funding, among others. Hence, Africa’s huge dependency on imported medications, including HIV drugs, has been contributing to its high cost. The high cost of HIV drugs makes them unaffordable and inaccessible to people, specifically those from lower economic sections. Hence has been hampering the demand for HIV drugs in the region.

Africa HIV Drugs Market Trend:

Increasing Government & Non-Government Support Programs & Initiatives for HIV – The rise in the number of support programs as well as awareness initiatives by the government and non-government bodies has emerged as a significant market trend in Africa and is expected to propel market growth. For instance,

• In 2023, the HIV Treatment Surge initiative to increase the number of people living with HIV on anti-retroviral treatment was launched in Nigeria by Osun State with support from the US Centers for Disease Control and Prevention (US CDC).
• Similarly, in 2022, in cooperation with the Joint United Nations Programme on HIV/AIDS (UNAIDS) and with leading pharmaceutical company EVA Pharma, the National AIDS Control Program at Egypt’s Ministry of Health and Population launched a new campaign to fight discrimination against people infected with HIV and address societal fears around the disease.

Such initiatives and programs have not only been providing detailed information about the disease, including available diagnosis and treatment options such as HIV drugs but have also been helping people who do not have access to or cannot afford appropriate treatment. Also, these awareness programs help in increasing the number of diagnosed cases of HIV-infected individuals, which require treatment. Thus, with multiple awareness initiatives and patient programs following HIV in Africa, the demand for HIV drugs would witness a rise, thereby propelling overall market growth & development.

Africa HIV Drugs Market (2024-30): Segmentation Analysis

The Africa HIV Drugs Market study of MarkNtel Advisors evaluates & highlights the major trends and influencing factors in each segment. It includes predictions for the period 2024–2030 at the regional level. According to the analysis, the market has been further classified as:

Based on Drug Class

• Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
• Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)-
• Protease Inhibitors
• Integrase Inhibitors
• Fusion Inhibitors-Vector
• Coreceptor Antagonists
• Combination HIV Drugs
• Others (Pharmacokinetic Enhancers, Capsid Inhibitors, etc.)

Out of them all, the non-nucleoside reverse transcriptase inhibitors (NNRTIs) segment held a major market share. NNRTIs have been observed to play a crucial role in first-line HIV treatment protocols as recommended by the World Health Organization (WHO). Their effectiveness in suppressing HIV replication and reducing viral load has made them a cornerstone of HIV therapy, particularly in resource-limited settings where cost-effectiveness is paramount.

Additionally, the availability of generic formulations of NNRTIs has facilitated greater access to these medications in Africa, as they tend to be more affordable than branded alternatives. Also, as African countries continue to scale up their HIV treatment programs and strive to achieve the ambitious targets set by global initiatives like UNAIDS' 90-90-90 goals, NNRTIs are going to remain essential components of HIV treatment regimens, driving demand and propelling the overall market for HIV drugs in Africa.

Based on the Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

The retail pharmacies segment accounted for the largest share of the Africa HIV Drugs Market. The presence of retail pharmacies across Africa helped improve access to HIV medications for individuals living with the virus by providing convenient points of distribution in urban and rural areas alike. This accessibility has been essential for ensuring that patients easily receive their prescribed medications and adhere to their treatment regimens, ultimately leading to better health outcomes. Also, the new retail pharmacies opening in countries like Egypt, South Africa, etc., would further propel segmental growth. For instance,

• In 2021, Clicks, the leading South African pharmacy chain, opened its 600th in-store pharmacy in South Africa.

Thus, with the expansion of retail pharmacies, they are further expected to cater to a larger number of customers who intend to buy different medications, including HIV drugs, which would impact the Africa HIV Drugs Market positively.

Africa HIV Drugs Market (2024-30): Regional Projections

Geographically, the Africa HIV Drugs Market expands across:

• South Africa
• Algeria
• Nigeria
• Kenya
• Uganda
• Rest of Africa

Kenya experienced substantial growth in the Africa HIV Drugs Market owing to several factors. The country has made significant strides in expanding access to HIV treatment and care services through initiatives such as the Kenya AIDS Strategic Framework and the Kenya National AIDS Strategic Plan. These efforts have led to increased testing, earlier diagnosis, and improved treatment coverage, driving demand for HIV drugs. Additionally, Kenya has a well-established healthcare infrastructure, including a network of clinics, hospitals, and pharmacies, which has been facilitating the delivery of HIV medications to individuals living with the virus and fosters a favorable environment for pharmaceutical companies and healthcare providers.

Moreover, Kenya has demonstrated a commitment to innovation and collaboration in the fight against HIV/AIDS, with partnerships between the government, non-profit organizations, and the private sector driving research, development, and implementation of new treatment strategies and technologies. These efforts would result in the expansion of the HIV drug market by introducing novel therapies, improving treatment outcomes, and attracting investment in the healthcare sector. Hence, Kenya is continuously taking essential steps to make affordable HIV treatment options available to its people, which would escalate the demand for HIV drugs in the country in the upcoming years.

Africa HIV Drugs Industry Recent Development:

• 2022: Cipla and DNDi launched child-friendly 4-in-1 antiretroviral treatment for young children living with HIV in South Africa.
• 2022: ViiV Healthcare’s cabotegravir (CAB-LA) was approved by the Medicines Control Authority of Zimbabwe (MCAZ).

Gain a Competitive Edge with Our Africa HIV Drugs Market Report

1. The Africa HIV Drugs Market Report by Markntel Advisors provides a detailed & thorough analysis of market size, growth rate, competitive landscape, and key players. This comprehensive analysis helps businesses gain a holistic understanding of market dynamics & make informed decisions.
2. This report also highlights current market trends & future projections, allowing businesses to identify emerging opportunities & potential challenges. By understanding market forecasts, companies can align their strategies & stay ahead of the competition.
3. The Africa HIV Drugs Market Report aids in assessing & mitigating risks associated with entering or operating in the market. By understanding market dynamics, regulatory frameworks, and potential challenges, businesses can develop strategies to minimize risks & optimize their operations.